Polymyxins leading to nephrotoxicity
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20233202Keywords:
Gram-negative , Polymyxins, Colistimethate sodium, MCR genes, Monte Carlo simulations, DosingAbstract
Drug resistance gram-negative bacteria are the most hazardous type of germ because they cause life-threatening illnesses. Polymyxins are cyclic lipodecapeptide antibiotics that are effective against gram-negative bacteria like Acinetobacter, Pseudomonas, and other Enterobacteriaceae (such Klebsiella, Escherichia coli, and Serratia). Polymyxins kill bacteria by rupturing the bacterial outer membrane (OM). The main side effect of this antibiotic class is the development of kidney damage. Transposable genetic elements, such as MCR genes, can encode bacterial resistance to polymyxins. Colistin's prodrug is colistimethate sodium (CMS). Polymyxin dosage should be modified based on renal function. Polymyxins have demonstrated excellent clinical results, which have aided in the development of a better dosage regimen. Monte Carlo simulations were used to determine the most effective polymyxin dosages. Polymyxin resurgence has resulted in the eradication of multidrug resistant gram negative bacteria.
Metrics
References
Dubashynskaya NV, Skorik YA. Polymyxin Delivery Systems: Recent Advances and Challenges. Pharmaceuticals (Basel). 2020;13(5):83.
Trimble MJ, Mlynárčik P, Kolář M, Hancock RE. Polymyxin: Alternative Mechanisms of Action and Resistance. Cold Spring Harb Perspect Med. 2016;6(10):a025288.
Vaara M. Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics. Molecules. 2019;24(2):249.
Azad MA, Huang JX, Cooper MA, Roberts KD, Thompson PE, Nation RL, et al. Structure-activity relationships for the binding of polymyxins with human α-1-acid glycoprotein. Biochem Pharmacol. 2012;84(3):278-91.
Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 2007;60(6):1206-15.
Mendes CA, Burdmann EA. Polymyxins - review with emphasis on nephrotoxicity. Rev Assoc Med Bras (1992). 2009;55(6):752-9.
Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1):R27.
Mohapatra SS, Dwibedy SK, Padhy I. Polymyxins, the last-resort antibiotics: Mode of action, resistance emergence, and potential solutions. J Biosci. 2021;46(3):85.
Jiang X, Patil NA, Azad MAK, Wickremasinghe H, Yu H, Zhao J, et al. A novel chemical biology and computational approach to expedite the discovery of new-generation polymyxins against life-threatening Acinetobacter baumannii. Chem Sci. 2021;12(36):12211-20.
Avedissian SN, Scheetz MH. Does renal function matter for polymyxin B? Br J Clin Pharmacol. 2021;87(7):2629-32.
Molina J, Cordero E, Pachón J. New information about the polymyxin/colistin class of antibiotics. Expert Opin Pharmacother. 2009;10(17):2811-28.
Moubareck C. Polymyxins and Bacterial Membranes: A Review of Antibacterial Activity and Mechanisms of Resistance. Membranes (Basel). 2020;10(8):181.
Cannatelli A, Giani T, Antonelli A, Principe L, Luzzaro F, Rossolini GM. First Detection of the mcr-1 Colistin Resistance Gene in Escherichia coli in Italy. Antimicrob Agents Chemother. 2016;60(5):3257-8.
Cannatelli A, Giani T, Antonelli A, Principe L, Luzzaro F, Rossolini GM. First Detection of the mcr-1 Colistin Resistance Gene in Escherichia coli in Italy. Antimicrob Agents Chemother. 2016;60(5):3257-8.
Mulvey MR, Mataseje LF, Robertson J, Nash JH, Boerlin P, Toye B, et al. Dissemination of the mcr-1 colistin resistance gene. Lancet Infect Dis. 2016;16(3):289-90.
Li B, Yin F, Zhao X, Guo Y, Wang W, Wang P, et al. Colistin Resistance Gene mcr-1 Mediates Cell Permeability and Resistance to Hydrophobic Antibiotics. Front Microbiol. 2020;10:3015.
Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother. 2012;56(9):4625-9.
Jian L, Nation R, Kaye K. Polymyxin Antibiotics: From Laboratory Bench to Bedside. Adv Exp Med Biol. 2019.
Zhang N, Zhu L, Ouyang Q, Yue S, Huang Y, Qu S, et al. Visualizing the Potential Impairment of Polymyxin B to Central Nervous System Through MR Susceptibility-Weighted Imaging. Front Pharmacol. 2021;12:784864.
Neiva LB, Borges FT, Watanabe M, Pessoa Ede A, Barbosa DA, Vattimo Mde F. Nephrotoxicity of polymyxin B: experimental study in cells and implications for nursing practice. Rev Esc Enferm USP. 2014;48(2):272-7.
Dai C, Xiao X, Li J, Ciccotosto GD, Cappai R, Tang S, et al. Molecular Mechanisms of Neurotoxicity Induced by Polymyxins and Chemoprevention. ACS Chem Neurosci. 2019;10(1):120-31.
Javan A, Shokouhi S, Sahraei Z, Salamzadeh J, Azad Armaki S. Nephrotoxicity of High and Conventional Dosing Regimens of Colistin: A Randomized Clinical Trial. Iran J Pharm Res. 2017;16(2):781-90.
Topete VH, Dios KJ, Casas GA, Hernandez SG, Lopez VCE, Torres ELM, et al. Adverse Events and Drug Resistance in Critically Ill Patients Treated with Colistimethate Sodium: A Review of the Literature. Infect Drug Resist. 2023;16:1357-66.
Brown P, Abbott E, Abdulle O, Boakes S, Coleman S, Divall N, et al. Design of Next Generation Polymyxins with Lower Toxicity: The Discovery of SPR206. ACS Infect Dis. 2019;5(10):1645-56.
Xia GL, Jiang RL. Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections. BMC Infect Dis. 2021;21(1):1034.
Cheah SE, Li J, Tsuji BT, Forrest A, Bulitta JB, Nation RL. Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance. Antimicrob Agents Chemother. 2016;60(7):3921-33.
Jahidul M, Rabbani R, Bachar SC. Therapeutic Specification of the Last Resort Polymyxins: An Intelligent Approach. Int J Infect. 2019.
Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72(6):857-68.
Ni M, Meng X, Wang L, Zhao Y, Yu M, Shi S. Polymyxin B-induced rhabdomyolysis: A case report. Medicine (Baltimore). 2020;99(43):e22924.
Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev. 2008;21(3):449-65.
Nang SC, Azad MAK, Velkov T, Zhou QT, Li J. Rescuing the Last-Line Polymyxins: Achievements and Challenges. Pharmacol Rev. 2021;73(2):679-728.
Dai C, Wang Y, Sharma G, Shen J, Velkov T, Xiao X. Polymyxins-Curcumin Combination Antimicrobial Therapy: Safety Implications and Efficacy for Infection Treatment. Antioxidants (Basel). 2020;9(6):506.
Chung JH, Bhat A, Kim CJ, Yong D, Ryu CM. Combination therapy with polymyxin B and netropsin against clinical isolates of multidrug-resistant Acinetobacter baumannii. Sci Rep. 2016;6:28168.
Thamlikitkul V, Dubrovskaya Y, Manchandani P, Ngamprasertchai T, Boonyasiri A, Babic JT, et al. Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. Antimicrob Agents Chemother. 2016;61(1):e01337-16.
Zou D, Yao G, Shen C, Ji J, Ying C, Wang P, et al. The Monte Carlo Simulation of Three Antimicrobials for Empiric Treatment of Adult Bloodstream Infections With Carbapenem-Resistant Enterobacterales in China. Front Microbiol. 2021;12:738812.
Downloads
Published
How to Cite
Issue
Section
